Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Entry of Stock Companies into Medical Field Does Not Put People's Lives at Risk
August 11, 2003
- Kirin Licenses Human Antibody Technology to Takeda
August 11, 2003
- Aventis' Ketek, Japan's 1st Ketolide Approved
August 11, 2003
- Evotec Neuroscience, Takeda to Collaborate in Drug Discovery for Alzheimer's Disease
August 11, 2003
- BUSINESS NEWS IN BRIEF
August 11, 2003
- Planning to Apply for 20 Drugs by 2006: Mr McKinnell of Pfzier
August 11, 2003
- MEDICAL DEVICE NEWS IN BRIEF
August 11, 2003
- DIAGNOSTIC NEWS IN BRIEF
August 11, 2003
- NEW PRODUCTS
August 11, 2003
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
August 11, 2003
- Warning against Facile Use of Antibiotics to Treat Colds: JRS GL
August 11, 2003
- GE Maker Group Reports Patent Status in EU
August 4, 2003
- Clear Identification of Drugs Essential to Prevent Medical Accidents: JHP Seminar
August 4, 2003
- Bayer Introduces "Frontline" Marketing Support System
August 4, 2003
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
August 4, 2003
- Remicade Receives Additional Indication for RA: Tanabe
August 4, 2003
- Nichiiko Considers Revising 3-Year Management Goals Upward
August 4, 2003
- Korosho Study Group Prepares Comprehensive GL on Lung Cancer
August 4, 2003
- PPTA Submits Comments on Blood Law to Korosho
August 4, 2003
- Only 35% of Migraine Sufferers Get Treatment
August 4, 2003
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…